Purpose: To evaluate the long-term efficacy and safety of trabeculectomy with or without low dosage Mitomycin-C (MMC) in primary open angle glaucoma (POAG).
Methods: 114 patients affected by POAG, participating in a randomized clinical trial from 1995 to 1998, were re-examined and their chart reviewed. Patients had undergone in one eye a trabeculectomy with intraoperative application (2 min) of MMC (0.2 mg/ml) or balanced saline solution (BSS), and, if indicated, post-operative laser suture lysis, bleb needling and/or digital massage. Intraocular pressure (IOP), medical therapy, visual field, further glaucoma surgery, cataract surgery, complication rate (leakage, cataract progression, hypotony, blebitis, endophthalmitis) were evaluated.
Results: 67 eyes had received MMC and 47 BSS. MMC-treated eyes had lower mean IOP (13.33+3.35 vs. 14.72+2.19 mmHg, P=0.014); in this group, an higher percentage of eyes had IOP¡Ü18 mmHg (73.1% vs. 51.1%, P=0.027) and IOP¡Ü14 mmHg (56.7% vs. 31.9%, P=0.015); a lower rate had further glaucoma surgery (9% vs. 25.5%, P=0.040), and visual field damage progression (21.1% vs. 48.6%, P=0.009). No difference was seen in the complication rate: one MMC-treated eye developed blebitis.
Conclusions: In POAG low-dose MMC with intensified post-operative management improved the outcome of the trabeculectomy with a low incidence of complications.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.